Delcath Systems Shares New Data on HEPZATO KIT™
Delcath Systems, Inc. (Nasdaq: DCTH) is making waves in the field of interventional oncology after unveiling fresh findings at a prominent medical congress. The focus of their presentation was their flagship product, HEPZATO KIT™, which targets the treatment of metastatic uveal melanoma (mUM) patients.
Highlights from the FOCUS Phase 3 Trial
The FOCUS Phase 3 trial serves as a pivotal study assessing the safety and effectiveness of the HEPZATO KIT™ for those dealing with unresectable hepatic metastases stemming from mUM. The study enrolled 102 participants and treated 91 of them, with key objectives centered on the objective response rate (ORR) and secondary goals revolving around progression-free survival (PFS) and overall survival (OS).
Positive Responses from the Trial Results
The trial results indicated a notable consistency in both ORR and PFS, with no significant differences emerging between subgroups, whether they had extrahepatic disease or varying treatment histories. A critical finding was that larger liver tumor burdens were linked to poorer overall survival rates. This insight is crucial for shaping future treatment strategies.
Long-term Benefits Observed
Throughout the treatment process, objective tumor responses were recorded at different stages. This highlights an ongoing treatment approach that emphasizes continued care until patients achieve the best possible results. Significantly, serious adverse events were infrequent, suggesting that HEPZATO KIT™ has a strong safety profile among patients.
Support from Key Opinion Leaders
Experts in the field, including Dr. Matthew Wheater, have praised these findings, noting the importance of achieving consistent results regardless of the presence of extrahepatic lesions. This reassuring data is especially encouraging for patients who typically encounter limited treatment options, particularly when it comes to liver-targeted therapies.
About Delcath Systems, Inc.
Delcath Systems, Inc. is committed to improving the lives of patients facing primary and metastatic liver cancers. The company is well-known for its innovative treatment options, especially the HEPZATO KIT™, which is designed to deliver concentrated doses of chemotherapy directly to the liver, reducing systemic side effects.
Details on HEPZATO KIT™ and CHEMOSAT
The HEPZATO KIT™ combines melphalan, a well-established chemotherapeutic agent, with Delcath's proprietary Hepatic Delivery System (HDS). This HDS isolates hepatic blood, maximizing the therapeutic effects while managing potential side effects. The FDA classifies HEPZATO KIT™ as a dual product that acts as both a drug and a device, approved for targeting mUM under specific liver involvement criteria.
Conclusion
The advancements reported by Delcath Systems not only underscore the potential of HEPZATO KIT™ in treating metastatic uveal melanoma but also signal a hopeful path forward for patients facing tough diagnoses. With its dedication to innovation and patient care, Delcath solidifies its position as a leader in oncological therapeutics.
Frequently Asked Questions
What is the HEPZATO KIT™ used for?
HEPZATO KIT™ is designed to deliver targeted chemotherapy for patients with metastatic uveal melanoma showing unresectable hepatic metastases.
What were the main findings of the FOCUS Phase 3 trial?
The FOCUS trial demonstrated that HEPZATO KIT™ provides consistent efficacy and safety, with no significant differences in outcomes based on the presence of extrahepatic disease.
Who presented the new data at ESMO 2024?
Dr. Matthew Wheater from University Hospital Southampton shared the new subgroup analysis data during the European Society for Medical Oncology Congress.
How many patients were involved in the trial?
A total of 102 patients participated in the FOCUS trial, with 91 receiving treatment using HEPZATO KIT™.
What is the significance of the results for patients?
The findings suggest that HEPZATO KIT™ offers a promising treatment option for patients who generally have few therapeutic choices, highlighting its favorable benefit-risk profile.
